Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BERGAMOT: Etrolizumab in Crohn's Disease
NCT02394028Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2015
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 3 trial of Etrolizumab in Crohn's disease, sponsored by Roche. Started Mar 2015; status: completed.
02
Drugs
Etrolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02394028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394028.